BioNexus Gene Lab SG&A Expenses 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BioNexus Gene Lab sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BioNexus Gene Lab sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$120.6B
Cencora (COR)	$44.1B
ICON (ICLR)	$23.6B
DiDi Global (DIDIY)	$22.4B
Avantor (AVTR)	$17.7B
Revvity (RVTY)	$15.6B
Natera (NTRA)	$15.3B
Viatris (VTRS)	$13.9B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$11.8B
Charles River Laboratories (CRL)	$10.2B
Medpace Holdings (MEDP)	$10.1B
Sonic Healthcare (SKHHY)	$9.1B
Doximity (DOCS)	$7.9B
HealthEquity (HQY)	$6.9B
Bausch + Lomb (BLCO)	$6.7B
PACS (PACS)	$6B
Organon (OGN)	$4.9B
Life Times (LTH)	$4.9B
Sotera Health (SHC)	$4.7B
Surgery Partners (SGRY)	$4.1B
Concentras Parent (CON)	$2.9B
Ardent Health Partners (ARDT)	$2.7B
GoodRx Holdings (GDRX)	$2.5B
BrightSpring Health Services (BTSG)	$2.5B
Alignment Healthcare (ALHC)	$2.1B
Premier (PINC)	$2B
Ryman Healthcare (RYHTY)	$2B
AMN Healthcare Services Inc (AMN)	$1.6B
CareDx (CDNA)	$1.6B